Matthew Rabinowitz is a distinguished figure in the biotechnology industry, currently serving as the Executive Chairman of Natera, Inc. With a strong background in genetics and bioinformatics, Rabinowitz has been instrumental in driving Natera's growth and innovation since its inception. He co-founded the company in 2003 and has played a pivotal role in its development into a leading provider of genetic testing and diagnostics. Under his leadership, Natera has expanded its product portfolio and established itself as a key player in the field of personalized medicine. Rabinowitz's professional journey is marked by significant achievements in both academia and industry. He holds a Ph.D. in Bioinformatics from Stanford University, where he conducted groundbreaking research in genomics and computational biology. His expertise in these areas has been crucial in developing Natera's proprietary technologies, such as the company's non-invasive prenatal testing (NIPT) and oncology diagnostics. Rabinowitz's strategic vision and commitment to scientific excellence have earned him recognition as a thought leader in the biotech sector. As Executive Chairman, Matthew Rabinowitz continues to guide Natera's strategic direction and oversee its operations. He works closely with the company's leadership team to ensure that Natera remains at the forefront of genetic testing innovation. Rabinowitz's dedication to improving patient outcomes through advanced diagnostics has been a driving force behind Natera's mission to make personalized medicine accessible to all. His leadership and vision have positioned Natera for continued success in the rapidly evolving field of genomics.